oxLDL as a predictive marker

oxLDL as a predictive marker for arrhythmogenic cardiomyopathy

20.01.2022

The study by Sommariva E et al. (2021) demonstrates that oxLDL can be used as a predictive marker for the progression of arrhythmogenic cardiomyopathy (ACM). Based on the cut-off of 86 ng/mL, patients with ACM were divided into 2 groups and further studied.
Levels < 86 ng/mL included among other things a lower risk of cardiovascular events (such as ventricular tachycardia, ventricular fibrillation, sudden cardiac death), improved cardiac function, and low fatty infiltration in the heart.

Thus, the oxLDL/MDA Adduct ELISA of IDK® can not only detect particularly small, modified oxLDL particles (Pfützner A et al.; 2009) and thus indicate changes in atherosclerosis risk, but can also be used as a predictive marker for arrhythmogenic cardiomyopathies.

Further source:
Pfützner A, Efstrathios K, Löbig M, Armbruster FP, Hanefeld M, Forst T. Differences in the results and interpretation of oxidized LDL cholesterol by two ELISA assays--an evaluation with samples from the PIOstat study. Clin Lab. 2009;55(7-8):275-81. PMID: 19894406.

Subscribe to Newsletter

Would you like to be informed about the latest news in the future? Then simply subscribe to our newsletter.

Register Don't show this again

This might also be of interest